Group 1: Event Overview - The eighth China International Import Expo (CIIE) is set to take place in 100 days, with over 50 countries and international organizations confirming participation [1] - The exhibition area for commercial exhibits has exceeded 330,000 square meters, with 170 companies and 27 institutions confirmed as "full attendance" participants [1] - Notable countries such as Canada, Malaysia, New Zealand, Norway, and Peru are participating with record-scale enterprises [1] Group 2: Company Participation and Innovations - NYO3, a well-known brand from Norway, will showcase a new product line called "Salmon Triad" at the expo, focusing on weight management, skin care, and bone health [1] - NYO3 is also planning to open its first brand store in Shanghai and is exploring becoming an investor by establishing production, R&D, and marketing in China [2] - D商集团 will display nearly 200 products, including premium beef and lamb, and aims to create an efficient model of "overseas production + domestic distribution" [2] Group 3: Hong Kong Participation - The Hong Kong Trade Development Council (HKTDC) has organized nearly 400 Hong Kong companies to participate over the past seven years, with a total exhibition area of nearly 10,000 square meters [3] - HKTDC will set up "Hong Kong Products Pavilion" and "Hong Kong Services Pavilion," including live streaming capabilities for exhibitors [3] - Last year, HKTDC facilitated around 1,000 business matching meetings, leading to collaborations between Hong Kong businesses and e-commerce platforms [3] Group 4: Medical Technology Innovations - The medical exhibition area will feature 10 Fortune 500 pharmaceutical companies and major players in medical imaging and radiation therapy [3] - GE Healthcare will present over 10 innovative products, including the ViewPoint 6 ultrasound data management platform, which enhances data management efficiency [4][5] - Boston Scientific will showcase over 80 innovative products, including five new products targeting various medical conditions, and has successfully transitioned 22 products from exhibition to market approval in China [6]

Group 1 - Boston Scientific is confirmed as one of the first multinational medical companies to participate in the 9th China International Import Expo (CIIE) scheduled for 2026 [1] - The company aims to leverage the CIIE platform to better understand local clinical needs and accelerate the introduction of innovative products tailored to China's healthcare landscape [4][11] - Boston Scientific has a strong history of innovation, with over 10% of its revenue invested in R&D annually and multiple products recognized with prestigious awards [5] Group 2 - At the 8th CIIE, Boston Scientific will showcase over 80 innovative products, including five that will have their debut, addressing various clinical needs such as liver tumors and atrial fibrillation [7] - The company has successfully transitioned 22 products from exhibition to market approval in mainland China, demonstrating the effectiveness of the CIIE as a platform for commercialization [10] - The CIIE serves as a unique value proposition for connecting global innovations with China's clinical demands, acting as an accelerator for healthcare technology [11] Group 3 - The establishment of Boston Scientific's first manufacturing base in China, completed within a year, highlights the efficiency and speed of operations in the country, enhancing the company's local strategy [11] - The company emphasizes the importance of digitalization and precision in responding to the evolving healthcare needs in China, aligning with national health initiatives [11]

Market Overview - The A-share market faced resistance at 3600 points due to the rapid decline of the Yasha Hydropower Station, while the Hong Kong market dropped 1.09% amid uncertainties for the upcoming week [1] - Trump's visit to the Federal Reserve is seen as an attempt to pressure Powell for a quicker interest rate cut, although a rate cut in July seems unrealistic [1] - The upcoming US-China talks scheduled from July 27 to 30 in Sweden may influence market sentiment, particularly regarding TikTok's operations in the US [1] Technology Sector - The 2025 World Artificial Intelligence Conference in Shanghai is set to showcase over 800 companies and 3000 cutting-edge exhibits, indicating strong market interest in AI technologies [2] - Huawei's Ascend 384 super node is a focal point of attention, with significant advancements in the domestic lithography machine industry expected to accelerate the localization process [3] Southeast Asia Market Expansion - Companies like Jihong Holdings and Lion Group are focusing on Southeast Asia, with Jihong expected to achieve a net profit of approximately 130 to 137 million yuan in the first half of 2025, marking a year-on-year growth of 97.25% to 108.21% [4] - Lion Group's partnership with China Post Hong Kong aims to create an AI-driven digital trade platform for Chinese brands entering Southeast Asia [4] Shipping Industry - Derxiang Shipping reported a 38.5% increase in revenue to approximately $326 million in Q1, driven by a 39.1% rise in average freight rates [9] - The company is expanding its service network with new routes and has a strong focus on the Middle East and Indian subcontinent, which are expected to drive future growth [11] Insurance Sector - The insurance industry is experiencing a "lock-in wave" due to a decrease in the predetermined interest rate for life insurance products, which is expected to boost new policy premiums in Q3 [7] - Major beneficiaries in the Hong Kong market include Zhong An Online, China Life, and China Pacific Insurance [8]

Core Insights - AI is rapidly entering the healthcare sector, with various AI-assisted diagnostic technologies maturing and new AI products attempting to integrate into different medical processes [1] - The biggest opportunity AI presents in healthcare is the accessibility of personalized medical services, but the rapid pace of change poses challenges for regulatory bodies [1] - There is a need for a more flexible and democratic regulatory framework to keep pace with the advancements in AI technology [4][5] Group 1: AI Technology in Healthcare - Companies are developing AI products for treating diseases like stroke, with capabilities for AI robots to autonomously perform surgeries under human supervision [2] - AI's ability to integrate diverse data types, such as medical imaging and patient history, allows for the creation of individualized treatment plans, enhancing precision medicine [2] - Current AI technologies primarily serve as decision-support tools, with clinical decisions still needing to be made by human doctors [2][3] Group 2: Regulatory Challenges - The regulatory landscape for AI in healthcare is multi-layered, involving drug regulatory agencies, health systems, and individual physicians, which can slow down the adoption of new technologies [3] - There is a consensus among industry experts that the existing regulatory frameworks are inadequate to address the rapid development of AI technologies [3][4] - A call for a more collaborative approach between the industry and government to establish a robust regulatory framework that prioritizes public safety and ethical standards [4][5]

Group 1 - Online learning platform Coursera saw a pre-market increase of over 22% [1] - Sports brand ANTA Sports experienced a pre-market rise of over 5% [1] - Medical technology company Clover Health rose by more than 3% in pre-market trading [1]

编辑：胡之澜 会议强调， 要强化统筹协调 ，完善工作机制，推动各项工作落地落实。 要加强政策保 障 ，将医工交叉融合创新纳入全市"十五五"产业发展规划，持续优化产业政策，强化服务 保障。 要加强复合型人才培养 ，支持高校设置相关专业、采取校企共建等方式培养人才， 积极引进国内外高端人才，为医工交叉融合创新提供智力支撑。 要强化安全治理 ，加强技 术安全和伦理安全管理，引导研发人员合规开展原创技术研究，促进产业健康可持续发展。 7月24日，市委召开专题会议研究深化医工交叉融合创新工作。省委常委、市委书记郭 元强主持会议并强调，要深入学习贯彻习近平总书记关于健康中国建设的重要论述和考察湖 北重要讲话精神，认真落实省委、省政府部署要求，以科技创新引领产业创新，大力推进医 工交叉融合创新，加快打造国际医疗创新高地。市委副书记、市长盛阅春出席会议并讲话。 市领导杨玲、陈劲超、曾晟、张俊勇、沈悦、张忠军参加会议。 会议指出， 新一轮科技革命和产业变革加速演进，医工交叉融合已成为科技创新和产 业创新的重要方向。 我市科教人才优势突出，医疗机构实力雄厚，应用场景丰富，产业基 础扎实，近年来积极推动医工交叉融合创新，大力发展生 ...

Core Viewpoint - The article discusses the challenges of diagnosing rare diseases and introduces DeepRare, an innovative AI-driven diagnostic system designed to improve the accuracy and efficiency of rare disease diagnosis [1][4][40]. Group 1: Rare Disease Challenges - Over 350 million people globally are affected by rare diseases, with more than 7,000 types identified, 80% of which are genetic [1]. - Patients often face significant delays in diagnosis, averaging over 5 years, with more than 7 consultations and 3 misdiagnoses, leading to a misdiagnosis rate of 40%-50% [1]. - The high heterogeneity of symptoms and fragmented information complicates the diagnostic process, making traditional AI models inadequate [2]. Group 2: DeepRare System Overview - DeepRare is the world's first reasoning-based intelligent diagnostic system for rare diseases, developed by Shanghai Jiao Tong University in collaboration with several institutions [4][6]. - The system utilizes a multi-agent architecture combined with large language models to simulate the diagnostic reasoning process of clinical doctors [6]. - It supports multi-modal inputs, including free text, structured phenotype data, and genomic data, allowing for adaptive responses to various input scenarios [8]. Group 3: Diagnostic Workflow and Performance - The diagnostic process in DeepRare consists of two main stages: gene analysis and knowledge matching, utilizing over 40 medical tools and databases for comprehensive reasoning [11][13]. - The system has shown significant performance improvements, with an average Recall@1 of 57.18%, surpassing existing methods by 23.79 percentage points [23]. - In real clinical cases, DeepRare achieved a Recall@1 of 70.6%, significantly outperforming Exomiser [33]. Group 4: Case Study and Impact - A case study highlighted the successful diagnosis of a 20-month-old child with Prader-Willi syndrome using DeepRare, which had previously gone undiagnosed [18][19]. - The system's ability to provide accurate diagnostic suggestions not only aids in clinical decision-making but also offers hope to families facing undiagnosed conditions [20]. Group 5: Future Prospects - DeepRare represents a paradigm shift in rare disease diagnosis, with potential applications in research to accelerate the interpretation of ambiguous variants and expand treatable rare diseases [40][41]. - The online platform for DeepRare has been launched, facilitating structured input and diagnostic suggestions for clinical doctors [38].

一、董事会会议召开情况 事会第四十二次会议已于 2025 年 7 月 17 日通过电子邮件方式通知了全体董事。 席董事 9 名（其中董事刘冰、肖薇以现场方式参加会议，其他董事以通讯方式参 加会议）。公司监事及高级管理人员列席了本次会议。 等法律、法规及《公司章程》的有关规定，合法有效。 经与会董事认真审议，充分讨论，审慎表决，会议审议通过了以下议案： 证券代码：301370 证券简称：国科恒泰 公告编号：2025-045 国科恒泰（北京）医疗科技股份有限公司 公司独立董事张金鑫已向董事会提交辞职报告，其因个人工作安排申请辞去 公司独立董事职务，同时不再担任公司第三届董事会审计委员会主任委员、薪酬 与考核委员会委员、提名委员会委员，其原定任期至 2025 年 12 月 11 日，辞职 后不再担任公司任何职务。 张金鑫先生的辞职将导致公司独立董事人数少于董事会总人数的三分之一， 导致董事会专门委员会中独立董事所占比例不符合法律法规及《公司章程》的规 定，且缺少会计专业人士。根据《中华人民共和国公司法》《上市公司独立董事 管理办法》《公司章程》等有关规定，张金鑫先生的辞职报告将在公司补选新任 独立董事后生效。在此期 ...

证券代码：301370 证券简称：国科恒泰 公告编号：2025-047 国科恒泰（北京）医疗科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 国科恒泰（北京）医疗科技股份有限公司（以下简称"本公司"或"公司"） 第三届董事会第四十二次会议决定于 2025 年 8 月 11 日（星期一）召开 2025 年第三 次临时股东大会，现将本次会议有关事项通知如下： 一、召开会议的基本情况 大会。 行政法规、部门规章、规范性文件和《公司章程》的规定。 （1）会议召开的时间：2025年8月11日（星期一）下午14:30 （2）网络投票时间： 通 过深圳证 券交易所交易系统进行网络投票的时间为 2025 年8月 11日上午 通过深圳证券交易所互联网系统投票的具体时间为2025年8月11日上午9:15至下 午15:00的任意时间。 （1）现场投票：股东本人出席本次现场会议或者通过授权委托书委托他人出席 现场会议； （2）网络投票：本次股东大会通过深圳证券交易所交易系统和互联网投票系统 （http://wltp.cninfo.com.cn）向全体股东提供网络形式的 ...

国科恒泰（北京）医疗科技股份有限公司 提名人国科恒泰（北京）医疗科技股份有限公司董事会 现就提名程小可先生为国科恒泰（北京）医疗科技股份有限 公司第三届董事会独立董事候选人发表公开声明。被提名人 已书面同意作为国科恒泰（北京）医疗科技股份有限公司第 三届董事会独立董事候选人（参见该独立董事候选人声明）。 本次提名是在充分了解被提名人职业、学历、职称、详细的 工作经历、全部兼职、有无重大失信等不良记录等情况后作 出的，本提名人认为被提名人符合相关法律、行政法规、部 门规章、规范性文件和深圳证券交易所业务规则对独立董事 候选人任职资格及独立性的要求，具体声明并承诺如下事项： 一、被提名人已经通过国科恒泰（北京）医疗科技股份 有限公司第三届董事会提名委员会资格审查，提名人与被提 名人不存在利害关系或者其他可能影响独立履职情形的密 切关系。 ? 是 □ 否 如否，请详细说明： 二、被提名人不存在《中华人民共和国公司法》第一百 七十八条等规定不得担任公司董事的情形。 ? 是 □ 否 如否，请详细说明： 三、被提名人符合中国证监会《上市公司独立董事管理 办法》和深圳证券交易所业务规则规定的独立董事任职资格 和条件。 ? ...